Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Systemic dysregulation of CEACAM1 in melanoma patients.

Markel G, Ortenberg R, Seidman R, Sapoznik S, Koren-Morag N, Besser MJ, Bar J, Shapira R, Kubi A, Nardini G, Tessone A, Treves AJ, Winkler E, Orenstein A, Schachter J.

Cancer Immunol Immunother. 2010 Feb;59(2):215-30. doi: 10.1007/s00262-009-0740-5.

PMID:
19633846
2.

CEACAM1 in malignant melanoma: a diagnostic and therapeutic target.

Sapoznik S, Ortenberg R, Schachter J, Markel G.

Curr Top Med Chem. 2012;12(1):3-10. Review.

PMID:
22196267
3.

Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients.

Sivan S, Suzan F, Rona O, Tamar H, Vivian B, Tamar P, Jacob S, Gal M, Michal L.

Clin Dev Immunol. 2012;2012:290536. doi: 10.1155/2012/290536. Epub 2012 Jan 16.

4.

CEACAM1-3S Drives Melanoma Cells into NK Cell-Mediated Cytolysis and Enhances Patient Survival.

Ullrich N, Heinemann A, Nilewski E, Scheffrahn I, Klode J, Scherag A, Schadendorf D, Singer BB, Helfrich I.

Cancer Res. 2015 May 1;75(9):1897-907. doi: 10.1158/0008-5472.CAN-14-1752. Epub 2015 Mar 5.

5.

CD8 T cells expressing NK associated receptors are increased in melanoma patients and display an effector phenotype.

Casado JG, Soto R, DelaRosa O, Peralbo E, del Carmen Muñoz-Villanueva M, Rioja L, Peña J, Solana R, Tarazona R.

Cancer Immunol Immunother. 2005 Dec;54(12):1162-71. Epub 2005 May 12.

PMID:
15889254
6.

The tumour suppressor gene CEACAM1 is completely but reversibly downregulated in renal cell carcinoma.

Kammerer R, Riesenberg R, Weiler C, Lohrmann J, Schleypen J, Zimmermann W.

J Pathol. 2004 Nov;204(3):258-67.

PMID:
15476270
7.

Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients.

Konjević G, Mirjacić Martinović K, Vuletić A, Jović V, Jurisić V, Babović N, Spuzić I.

Clin Exp Metastasis. 2007;24(1):1-11. Epub 2007 Feb 13.

PMID:
17295095
8.

Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: decreased NKG2D and increased CD158a receptors on CD3-CD16+ NK cells.

Konjević G, Mirjacić Martinović K, Jurisić V, Babović N, Spuzić I.

Biomarkers. 2009 Jun;14(4):258-70. doi: 10.1080/13547500902814658.

PMID:
19489688
9.

The involvement of NK cells in ankylosing spondylitis.

Azuz-Lieberman N, Markel G, Mizrahi S, Gazit R, Hanna J, Achdout H, Gruda R, Katz G, Arnon TI, Battat S, Zamir E, Adawi M, Mader R, Mandelboim O.

Int Immunol. 2005 Jul;17(7):837-45. Epub 2005 Jun 3.

PMID:
15937057
10.

The human antibody fragment DIATHIS1 specific for CEACAM1 enhances natural killer cell cytotoxicity against melanoma cell lines in vitro.

Dupuis ML, Fiori V, Soriani A, Ricci B, Dominici S, Moricoli D, Ascione A, Santoni A, Magnani M, Cianfriglia M.

J Immunother. 2015 Nov-Dec;38(9):357-70. doi: 10.1097/CJI.0000000000000100.

11.

A phenotypic and functional characterization of NK cells in adenoids.

Mizrahi S, Yefenof E, Gross M, Attal P, Ben Yaakov A, Goldman-Wohl D, Maly B, Stern N, Katz G, Gazit R, Sionov RV, Mandelboim O, Chaushu S.

J Leukoc Biol. 2007 Nov;82(5):1095-105. Epub 2007 Aug 3.

PMID:
17675561
12.

Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions.

Ortenberg R, Sapir Y, Raz L, Hershkovitz L, Ben Arav A, Sapoznik S, Barshack I, Avivi C, Berkun Y, Besser MJ, Ben-Moshe T, Schachter J, Markel G.

Mol Cancer Ther. 2012 Jun;11(6):1300-10. doi: 10.1158/1535-7163.MCT-11-0526. Epub 2012 Mar 30.

13.

Natural killer receptors on CD8 T cells and natural killer cells from different HLA-C phenotypes in melanoma patients.

Campillo JA, Martínez-Escribano JA, Moya-Quiles MR, Marín LA, Muro M, Guerra N, Parrado A, Campos M, Frías JF, Minguela A, García-Alonso AM, Alvarez-López MR.

Clin Cancer Res. 2006 Aug 15;12(16):4822-31.

14.

Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells.

Carrega P, Pezzino G, Queirolo P, Bonaccorsi I, Falco M, Vita G, Pende D, Misefari A, Moretta A, Mingari MC, Moretta L, Ferlazzo G.

PLoS One. 2009 Dec 4;4(12):e8132. doi: 10.1371/journal.pone.0008132.

15.

CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients.

Speiser DE, Valmori D, Rimoldi D, Pittet MJ, Liénard D, Cerundolo V, MacDonald HR, Cerottini JC, Romero P.

Eur J Immunol. 1999 Jun;29(6):1990-9.

16.

Impaired perforin-dependent NK cell cytotoxicity and proliferative activity of peripheral blood T cells is associated with metastatic melanoma.

Jović V, Konjević G, Radulović S, Jelić S, Spuzić I.

Tumori. 2001 Sep-Oct;87(5):324-9.

PMID:
11765182
17.

The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.

Guillot B, Portalès P, Thanh AD, Merlet S, Dereure O, Clot J, Corbeau P.

Br J Dermatol. 2005 Apr;152(4):690-6.

PMID:
15840100
18.

Activation-induced expression of carcinoembryonic antigen-cell adhesion molecule 1 regulates mouse T lymphocyte function.

Nakajima A, Iijima H, Neurath MF, Nagaishi T, Nieuwenhuis EE, Raychowdhury R, Glickman J, Blau DM, Russell S, Holmes KV, Blumberg RS.

J Immunol. 2002 Feb 1;168(3):1028-35.

19.

NK cells, displaying early activation, cytotoxicity and adhesion molecules, are associated with mild dengue disease.

Azeredo EL, De Oliveira-Pinto LM, Zagne SM, Cerqueira DI, Nogueira RM, Kubelka CF.

Clin Exp Immunol. 2006 Feb;143(2):345-56.

20.

Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1.

Stern N, Markel G, Arnon TI, Gruda R, Wong H, Gray-Owen SD, Mandelboim O.

J Immunol. 2005 Jun 1;174(11):6692-701.

Supplemental Content

Support Center